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Abstract
Background: We have generated a series of isogenically derived immortalized human colonic epithelial cell (HCEC 1CT
and HCEC 2CT) lines, including parental un-immortalized normal cell strains. The CDK4 and hTERT immortalized colonic
epithelial cell line (HCEC 1CT) is initially karyotypically normal diploid and expresses a series of epithelial cell markers
including stem cell markers. Under stressful tissue culture conditions, a spontaneous aneuploidy event occurred in the
HCEC 1CT line, resulting in a single chromosomal change leading to a stable trisomy 7 cell line (1CT7). Trisomy 7 occurs
in about 40% of all benign human adenomas (polyps) and thus this specific chromosomal change in diploid HCEC 1CT
cells appears to be non random. In addition, we have partially transformed the HCEC 1CT line by introducing stable
knockdown of wild type APC and TP53, and ectopically introducing a mutant Krasv12 and a mutant version of APC
(A1309), all commonly found mutations in colorectal cancer (CRC).
Methods: Whole exome sequencing and bioinformatic analyses were performed to comprehensively examine the
genetic background of these isogenic cell lines.
Results: Exome sequencing of these experimentally progressed cell lines recapitulates a list of genes previously
reported to be involved in CRC tumorigenesis. In addition, sequencing revealed a collection of novel genes
specifically detected in 1CT7 and A1309 cells but not normal diploid 1CT cells.
Conclusion: This study demonstrates the utility of using isogenic experimentally derived HCEC lines as a model to
recapitulate CRC initiation and progression. Exome sequencing reveals a collection of novel genes that may play
important roles in CRC tumorigenesis.
Background
Colorectal cancer (CRC) is the third most commonly diag-
nosed cancer and third leading cause of cancer related
mortality in the United States. It is well established that
sporadic colorectal cancer (CRCs) arises through the
acquisition of a series of sequential genetic mutations in
both tumor suppressor genes and oncogenes [1]. Muta-
tional activation of oncogenes together with inactivation
of tumor suppressor genes (TSG) contributes to colorectal
tumor formation. It has been proposed that a minimum of
four sequential genetic alterations are required for colorec-
tal cancer evolution, including one oncogene (KRAS) and
three TSGs (APC, SMAD4, TP53) as the main targets [2].
The dominant or recessive nature of these genes predict
that at least seven mutations (KRAS and six additional
ones) are required for complete inactivation of important
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TSG function [2]. The TSG mutations occur in most
tumors, whereas KRAS mutations are found in approxi-
mately 50% of sporadic adenomas and carcinomas [3,4].
However, additional changes are required to convert a
normal colonic epithelial cell into a malignant carcinoma.
While most CRCs have ~100 or more genomic changes,
many of these are believed to be incidental or “passenger”
alterations, and it is estimated that up to 15 “driver” onco-
genic changes are required for transforming into full
malignancy [5]. Many of these changes are not frequently
observed in CRC and thus it remains to be determined
which less frequently mutated genes are involved in CRC
initiation and development.
Recent advances in next generation sequencing (NGS)
technology have allowed for rapid and efficient analysis of
causative mutations in rare Mendelian disorders [6]. Sev-
eral studies have demonstrated the utility of exome
sequencing in identifying novel driver mutations in various
cancer types [7-10]. In particular, the whole exome and
even the whole genome sequencing of colorectal tumors
have delineated a comprehensive mutational landscape of
genetic alterations in CRC [5,11,12]. However, the muta-
tional events that contribute to CRC initiation are less
well-studied, partly due to the lack of appropriate cellular
reagents for validating important changes. We reasoned
that examination of the landscape of genomic changes as
early events in CRC initiation could be determined by
introduction of specific alterations in the background of
normal diploid HCECs. In the present study, we applied
exome sequencing on a series of isogenically-derived
immortalized human colonic epithelial cell (HCEC) lines
generated from the same individual with defined genetic
manipulations. Analysis of the mutation spectrum of these
cell lines reveal expected changes and a list of novel candi-




The culture conditions of HCECs and their isogenic series
have been reported elsewhere [13]. Briefly, HCECs were
maintained under 2% oxygen and 5% carbon dioxide on
Primaria® (BD Biosciences, San Jose, CA) plates in
4:1 high-glucose Dulbecco modified Eagle medium/med-
ium 199 with 2% cosmic calf serum (Hyclone, Logan, UT)
plus growth supplements: epidermal growth factor (EGF;
20 ng/ml; Peprotech, Rocky Hill, NJ), hydrocortisone
(1 mg/ml), insulin (10 mg/ml), transferrin (2 mg/ml), and
sodium selenite (5 nM) (all Sigma, St Louis, MO).
DNA and RNA Extraction
DNA and RNA were extracted from cell lysates using a
DNeasy Blood & Tissue Kit or RNeasy Plus Mini Kit
(Qiagen, Valencia, CA) according to the manufacturer’s
instructions. Genomic DNA was used for exome
capture.
qRT-PCR
Total RNA was isolated from cells using RNeasyMinikit
(Qiagen, Chatsworth, CA) according to the manufacturer’s
protocol. Then 1 µg RNA was converted to cDNA using a
First Strand cDNA Synthesis Kit (Roche, Indianapolis, IN).
Real-time quantitative PCR reactions were set up in tripli-
cate with Ssofast Master Mix (Biorad, Hercules, CA) and
run on a LightCycler® 480 (Roche, Indianapolis, Indiana).
Sanger sequencing
PCR was performed on cDNA from each cell line and pur-
ified PCR products were directly sequenced. Each read was
aligned with reference sequence at Nucleotide BLAST
website (http://blast.ncbi.nlm.nih.gov/Blast.cgi?PRO-
GRAM=blastn&PAGE_TYPE=BlastSearch&LINK_LOC=-
blasthome ). The forward and reverse primers for INCENP
are: 5’-tctgcagggcagcaagag-3’ and 5’-tcctccttcatctgctccac-3’.
Whole-exome sequencing
Exome capture using 3 µg of genomic DNA from each cell
line was performed using the TargetSeq (TM) Exome
Enrichment system (A14061) from Life Technologies
according to the manufacturer’s protocol. Sequencing was
performed on the SOLiD(TM) 5500XL platform. Mapping
to the hg19 version of the human genome and single
nucleotide variations as well as small indels identification
was performed using default settings of the LifeScope soft-
ware (Life Technologies, Carlsbad, CA). High quality var-
iants (with coverage >=10x and MQV>=20) were
annotated and filtered using the SNP and Variation Suite
(SVS) version 7 from Golden Helix. Novel and rare var-
iants (with MAF <1%) were filtered against the NHLBI
exome project database. SNVs were predicted damaging
using the SIFT, Poly-Phen or the Mutation Taster software
within the SVS7 pipeline.
Results
Characteristics of the sequenced HCEC lines
The HCEC 1CT line used in these experiments was
derived from non-malignant colonic tissue from a patient
with a previous history of CRC who was undergoing rou-
tine colonoscopy screening. The cells derived from
explants were immortalized with ectopic expression of
CDK4 and hTERT as previously described [13]. This cell
line maintains a stable normal karyotype (46, XY) when
continuously propagated in 2% oxygen and medium con-
taining 2% serum [13]. 1CT7 cells were spontaneously
generated from 1CT cells after prolonged passage under
serum-free condition [14]. Trisomy in chromosome 7 is
one of the earliest events occurring in up to ~ 40% of colo-
nic benign adenomas [15-17]. 1CT7 cells have enhanced
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cell migration (in a scratch-wound assay) compared to
1CT cells when cultured under low (2%) oxygen condi-
tions (data not shown). Additionally, 1CT7 cells have sig-
nificant up-regulation of EGFR and c-Met, which are two
chromosome 7-located receptor tyrosine kinase compared
to 1CT cells [14]. 1CTRPA A1309 (abbreviated as A1309)
is a partially transformed cell line harboring TP53 and
APC knockdowns (>90%), as well as ectopic expression of
oncogenic KRASV12 and truncated APC1309, all of which
are common mutations detected in CRC tumors [1,2].
This cell line exhibits enhancement in cellular prolifera-
tion, anchorage independent growth as well as invasion
through Matrigel® compared with the 1CT line which
does not have any detectable tumorigenic characteristics.
Both 1CT7 and A1309 cell line are not fully transformed
because they lack the ability to form tumors in immuno-
compromised mice (data not shown).
Exome capture and sequencing results
Exome capture was performed on the three isogenic 1CT
cell lines using SOLiD(TM) 5500XL platform. A sum-
mary of the sequencing result is provided in Table 1. On
average, 57.6 % of the bases were covered to 10X within
the targeted bases. After mapping to the hg19 version of
human genome (http://genome.ucsc.edu), we obtained
the average depth of each read in the target region as
~19X, 21X, 11X for each sample. The average number of
observed variants for three samples is 11582. To filter
out neutral variants, SIFT and Poly-Phen or the Mutation
Taster analysis were performed to predict the functional
consequences of all the mutations. We focused our analy-
sis on the 240 and 280 genes with a minimum of three
“deleterious” variant reads that are specifically mutated in
1CT7 and A1309 cells, respectively (Additional file 1).
There are 32 genes altered found in common in both
cell types.
Mutation spectrum of the isogenic 1CT cell lines
To examine if the mutations identified in 1CT7 and A1309
cells are relevant in CRC initiation or progression, we com-
pared the high confidence mutations specifically present
within 1CT7 or A1309 cells as listed in additional file 1 (at
least six “deleterious” reads) with the TCGA CRC tumor
dataset for 212 cases ( http://www.cbioportal.org/public-
portal/ ). This analysis shows that the 1CT7 specific
mutated genes are altered in 30.4% of all CRC cases
whereas A1309 specific mutated genes are altered in 73.6%
of all CRC cases, among which five genes are known can-
cer genes, i.e. PBRM1, MYB, PRDM16, BCR and NUP214
(Figure 1). In particular, PTPRT (protein tyrosine phospha-
tase receptor type T), one of the 1CT7 specific mutated
gene that may be involved in cell adhesion is altered in
16.7% of the CRC cases [18]. Another example is the
A1309 specific mutated gene CSMD1 (CUB and shushi
multiple domain 1), that is a TSG altered in 15.6% of the
CRC cases [19]. The other frequently mutated genes, such
as SYNE1, MUC16, etc. have been found to be mutated in
other cancer types and may be novel candidate driver
mutations in early stage of CRC tumorigenesis [20,21].
Previously, exome sequencing of 24 randomly selected
colorectal adenomas revealed mutations involved in multi-
ple known CRC related pathways, such as Wnt signaling,
cadherin signaling, integrin signaling, inflammation, and
angiogenesis [22]. Comparison of cell autonomous specific
mutations found in the present study shows the overlap of
a subset of the genes implicated in these pathways (Addi-
tional file 2). Additionally, the distribution of all the high
confidence hits in the present study exhibited similar pat-
tern of biological processes to that of mutations detected
in those adenomas (Additional file 3). Among these activ-
ities, metabolic, cell communication and transport are the
most highly represented processes. Interestingly, a subset
of mutations detected in 1CT7 or A1309 cells clustered on
Table 1 Summary of exome sequencing results of three isogenic HCEC cell lines
Parameter 1CT 1CT7 A1309
Total reads 40157067 40491020 33924594
Total yield (bp) 2066960672 2078084457 1412998222
Mappable reads 33533312 33767043 25863504
Mappable yield (bp) 2514998400 2532528225 1939762800
On-target reads 14514230 13119148 8353753
On-target yield (bp) 37262779 37262779 37262779
Coverage of target region (more than 10x) 66.18% 65.34% 42.24%
Mean read depth of targeted region 20.99 19.06 10.79
Mean read depth of called variants 23.4 23.1 21.7
Number of total variants 14466 13791 6491
Number of coding variants 9841 9723 4990
Number of missense, nonsense, splice, and indel variants 4910 4895 2583
After NHLBI ESP6500 Exomes filtering 4071 3990 2050
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chromosome 11p15 (Additional file 4), consistent with a
previous report of numerous aberrations detected on
chromosome 11 in colorectal adenocarcinoma [23]. Taken
together, these results can be interpreted to suggest that
existence of trisomy 7 and the other introduced genetic
alterations lead to the acquisition of additional mutations
that may drive CRC initiation and progression.1CT7 and
partially transformed A1309 cells may harbor the genetic
background mimicking early stages CRC. In addition,
since many of these mutations are detected sequentially in
an experimental in vitro manipulated setting, it suggests
these mutations occur in a cell autonomous manner and
are not dependent on the extracellular microenvironment
that occurs in vivo.
Identification of novel candidate genes involved in CRC
tumorigenesis
To identify the genetic alterations that may be most rele-
vant in CRC tumorigenesis, we prioritized our candidate
genes using the ToppGene suite. This web-based tool has
been shown to be a useful portal in identifying novel dis-
ease candidate genes [24,25]. We built the training gene
set using the 24 colorectal adenoma sequencing data [22]
and the test set using the high confidence 1CT7 or A1309
specific mutations. Protein-protein interaction (PPIN)-
based methods, including K-Step Markov, Hits with
Priors, and PageRank with Priors, as well as functional
annotation-based prioritization were used for the analyses
(Additional file 5). The intersection of the top 20 genes
using each method for 1CT7 or A1309 is represented as a
Venn diagram in Figure 2. This analysis reveals 13 genes
in 1CT7 cells and 14 genes in A1309 cells that can be
designated as hits using more than three methods. To
investigate whether this collection of top ranked novel
candidate genes are potentially important in CRC biology,
we compare these 27 genes with the TCGA dataset. We
found that the 27 genes are altered in 35% of all the CRC
cases and the cases with these alterations show poorer
overall survival in Kaplan-Meier Plot analyses (Additional
file 6) compared to the cases without these alterations. We
then placed the 27 genes as central nodes and overlaid
them with the TCGA dataset. This leads to the generation
of an interaction network as shown in Additional file 7.
Within this network 15 out of 27 genes interact either
directly or indirectly and most, if not all of the interactors
are altered in CRC tumors. A subset of these interacting
Figure 1 Mutations specifically occurred in 1CT7 or A1309 cells are highly present in colorectal tumor samples. These two bar graphs display
the frequency of mutation or copy number alteration for each gene that have over six “deleterious” reads and are uniquely detected in 1CT7 or
A1309 cells. Data was retrieved from the TCGA database. (http://www.cbioportal.org/public-portal/)
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genes are known to be involved in CRC tumorigenesis,
such as AXIN2, FBXW7and PIK3CA whereas the rest of
the interacting genes do not have established roles in
CRC. Further Gene Set Enrichment Analysis (http://www.
broadinstitute.org/gsea/msigdb/annotate.jsp) of these 27
genes using C2 (except chemical and genetic perturbation
category) curated gene sets reveals the enrichment in mul-
tiple pathways, such as EGFR, endocytosis, FGFR, splice-
some and apoptosis (Additional file 8). Taken together,
these results could be interpreted to suggest that these 27
genes and their interactors may be novel candidate genes
that are involved in CRC tumorigenesis. Further mechan-
istic investigations of these genes and the pathways they
are implicated in may give insights into their role in CRC
initiation and progression and perhaps the identification
of novel therapeutic targets.
Identification of INCENP polymorphism in 1CT isogenic
series
The exome capture identified 3 single nucleotide poly-
morphisms (SNPs) in the INCENP gene in 1CT7 cells and
one of the variants, p.M506T is predicted to be deleterious
using SIFT analysis (Table 2). INCENP is a member of
chromosomal passenger complex (CPC) which also con-
sists of Aurora B, Survivin and Borealin [26]. Overexpres-
sion of INCENP is observed in several colorectal cancer
cell lines [27]. Validation by Sanger sequencing confirmed
that variant p.M506T is present in all 1CT series, i.e. 1CT,
1CT7 and A1309 as well as its pre-immortalized HCEC1
cells and this variant occurs at a highly conservative posi-
tion (Figure 3). Interestingly, this INCENP variant does
not occur in 2CT cell line which is an independent CDK4
and hTERT immortalized colonic epithelial cell line
derived from a patient with no CRC history. This cell line
did not acquire trisomy 7 as does 1CT when cultured
under the same serum deprived culture conditions. Since
INCENP plays important roles in mitosis [28], it is possi-
ble that mutations in this gene may be one of the contri-
buting factors that lead to aneuploidy and the occurrence
of trisomy 7 cells in 1CT cell population. Further func-
tional investigation is warranted to delineate its potential
role in aneuploidy and as an early event in CRC initiation.
Discussion
We performed whole exome sequencing of a series of iso-
genically derived human colonic epithelial cell lines
(HCECs), including the non-cancerous diploid parental
1CT cells, the 1CT7 cells with spontaneously occurring
trisomy 7 which is frequently observed as an early event in
CRC, and partially transformed A1309 cells harboring
commonly found mutations in CRC. On average, ~60 % of
the bases were covered to 10X within the targeted bases
with over 10,000 variants detected in these samples. The
reason we chose 1CT as the control cell line but not 2CT
or another known independent cell line is because 1CT,
1CT7 and A1309 are isogenically derived from the original
pre-immortalized patient cells. Thus, the genes specifically
mutated in 1CT7 and A1309 cells are more likely to be
candidate “driver” genes instead of “passengers” involved
in CRC tumorigenesis.
Based on the TCGA datasets examined, the mutations
unique to 1CT7 occurs in 30.4% of all CRC cases whereas
Figure 2 Venn Diagram comparing the top 20 ranked candidate genes for CRC tumorigenesis derived from 1CT7 and A1309 sequencing data
using functional annotation- and protein-protein interaction (PPIN)- based methods. Functional annotation-based prioritization was done using
ToppGene server. For PPIN-based methods, K-Step Markov, Hits with Priors, and PageRank with Priors were used.
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A1309 specific mutated genes are altered in 73.6% of all
CRC cases. 1CT7 is a premalignant cell line containing
only one early molecular change that occurs in about
40% of CRC cases. Additionally, many of the mutations
found in this cell line are likely to be incidental events.
Therefore, it is very likely amplification of chromosome 7
is an important early event in a reasonable fraction of
sporadic CRC. The top ranked genes, PTPRT and
CSMD1, which are unique to 1CT7 and A1309 cells,
respectively, have previously been reported to be mutated
in colorectal tumors [7,19]. Comparison of our sequen-
cing data with a previous exome sequencing study for 24
colorectal adenomas reveals the overlap of a subset of
genetic mutations involved in CRC related pathways.
These results suggest that the existence of trisomy 7 and
the introduction of other genetic manipulation can lead
to acquisition of additional genetic mutations that may
contribute to CRC progression. Interestingly, knockdown
of TP53 and expression of K-RasV12 in 1CT7 cells results
in the emergence of trisomy 20, another nonrandom
aneuploidy observed in ~85% of CRC [14]. Therefore,
1CT7 and partially transformed A1309 cells may harbor
the genetic background mimicking susceptibility to early
stage colon cancer initiation and progression. These cell
lines represent an ideal cell autonomous model to deline-
ate the molecular events that contribute to CRC
tumorigenesis.
Utilizing the ToppGene portal, we prioritized the can-
didate gene list based on protein-protein interactions and
other functional annotations. A total of 27 genes are
putative CRC hits using more than three methods. Many
of these genes are frequently mutated in CRC tumors
and patients with alteration in these genes exhibit overall
poorer survival. Network analysis of these genes reveals
Table 2 Characteristics of INCENP variants detected in this study
Cell line Genomic positions Nucleotide change Amino acid change Type Evolutionary conservation SIFT analysis*
1CT7 q12.3 c. T1517>C p. M506T Single AA change Yes 0.03
1CT7 q12.3 c.G1931>C p. E644D Single AA change Yes 0.101
1CT7 q12.3 c. T1187>C p.N396N Synonymous No 0.894
* Prediction of a change to be deleterious (<0.05) or tolerated.
Figure 3 Validation of “deleterious” INCENP variants in ICT series. Predicted “deleterious” mutation p.M506T was confirmed by Sanger
sequencing of PCR products from 1CT series. c. T1517>C mutation (highlighted in red box) was detected in all 1CT series as well as the pre-
immortalized HCEC1 cells and it occurs at a highly conserved position.
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additional and perhaps novel interactors that are also
altered in CRC tumors. Therefore, this set of genes and
their interacting partners may play important role in
CRC tumorigenesis.
Epigenetic regulation of gene silencing is another path-
way by which tumor suppressor genes are inactivated
[29]. Aberrant DNA methylation has been reported to
contribute to colon cancer progression through CpG
Island Methylator Phenotype (CIMP) [29,30]. We can
speculate that 1CT7 and A1309 cell lines may harbor a
higher presence of aberrantly methylated genes com-
pared to their normal isogenic counterpart, 1CT cells.
Future investigation of the epigenetic signatures of these
cell lines compared to preimmortalized normal epithelial
cells as well as the authentic CRC samples are warranted.
In conclusion, the present study revealed the compre-
hensive mutation spectrums of a series of isogenically-
derived HCEC lines. This has led to the identification of
known CRC genes as well as a collection of novel candi-
date CRC genes, demonstrating the potential of utilizing
these isogenic HCEC lines to unravel the early cell autono-
mous events that contribute to CRC initiation and pro-
gression. These newly identified important CRC “driver”
genes can be potentially utilized as biomarkers for the
diagnostic and prognostic applications. A collection of
these candidate genes may be further pursued as novel
therapeutic targets for CRC prevention and intervention.
Availability of supporting data
Raw sequencing data can be retrieved from DOI:
10.6070/H44M92HV.
Additional material
Additional file 1: List of genes specifically mutated in 1CT7 or
A1309 cells with at least three or six “deleterious” variant reads.
Functional consequence of the variants were predicted using SIFT,
Poly-Phen or the Mutation Taster softwares. Genes with variants
that have more than three or six “deleterious” or “damaging” reads
in either one of these analyses but are not present in 1CT cells
were selected.
Additional file 2: Comparison of exome sequencing data of 24
colorectal adenomas with our sequencing data. This table lists the
genes mutated in colorectal adenoma samples, 1CT7 or A1309 cells
that belong to the five known CRC related pathways. Overlapped
genes are highlighted in yellow or green.
Additional file 3: Distribution of mutations specifically occurred in
1CT7 or 1CTRPA A1309 cells as well as colorectal adenomas in
different biological processes. Red and blue bars display the
frequency of the A1309 or 1CT7 specific mutations that have over
three “deleterious” reads in each biological process category. Black
bar displays the mutations detected in colorectal adenomas from a
previous study[23].
Additional file 4: Summary of mutations detected in 1CT7 and
A1309 cells on chromosome 11p15.
Additional file 5: CRC candidate genes prioritization. This table lists
the top 20 ranked genes using each prioritization method in 1CT7
or A1309 cells.
Additional file 6: Kaplan-Meier plot of cases with or without the 27
genetic alterations. Cases with these alterations show poorer
overall survival. Data was retrieved from the TCGA database.
(http://www.cbioportal.org/public-portal/)
Additional file 7: Interaction map of prioritized genes identified
from our cells (thick border) and the genes found to be mutated in
CRC tumor samples (thin border). Interactions were colored
according to the type of interactions as shown in the color key.
This map is constructed from TCGA portal. (http://www.cbioportal.
org/public-portal)
Additional file 8: The pathways that the 27 prioritized genes are
enriched in. Gene set enrichment analysis was performed for the 27
top ranked candidate genes using C2 (except chemical and genetic
perturbation category) curated gene sets.
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